Veracyte inc VCYT.US 總覽分析
)VCYT 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
VCYT 近期報酬表現
1.20%
Veracyte inc
1.31%
同產業平均
0.58%
S&P500
與 VCYT 同產業的標的表現
- TWST Twist bioscience corp價值 3 分趨勢 1 分波段 2 分籌碼 3 分股利 1 分查看更多
VCYT 公司資訊
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.